Partnership of government, academics and industry will develop new ways of studying and screening drugs for major psychiatric illnesses
By Catherine Gara
The Johns Hopkins University School of Medicine and the Salk Institute for Biological Studies will co-lead a $15.4 million effort to develop new systems for quickly screening libraries of drugs for potential effectiveness against schizophrenia and bipolar disorder, the National Institute of Mental Health (NIMH) has announced.
The consortium, which includes four academic or nonprofit institutions and two industry partners, will be led by Hongjun Song, PhD, of Johns Hopkins and Rusty Gage, PhD, of Salk.
Bipolar disorder affects more than five million Americans, and treatments often help only the depressive swings or the opposing manic swings, not both. And though schizophrenia is a devastating disease that affects about 3 million Americans and many more worldwide, scientists still know very little about its underlying causes — which cells in the brain are affected and how — and existing treatments target symptoms only.
With the recent advance of induced pluripotent stem cell (iPSC) technology, researchers are able to use donated cells, such as skin cells, from a patient and convert them into any other cell type, such as neurons. Generating human neurons in a dish that are genetically similar to patients offers researchers a potent tool for studying these diseases and developing much-needed new therapies.
A major aim of this collaboration is to improve the quality of iPSC technology, which has been limited in the past by a lack of standards in the field and inconsistent practices among different laboratories.
“There has been a bottleneck in stem cell research,” says Song, a professor of neurology and neuroscience at Johns Hopkins. “Every lab uses different protocols and cells from different patients, so it’s really hard to compare results. This collaboration gathers the resources needed to create robust, reproducible tests that can be used to develop new drugs for mental health disorders.”
“IPSCs are a powerful platform for studying the underlying mechanisms of disease,” says Gage, a professor of genetics at Salk. “Collaborations that bring together academic and industry partners, such as this one enabled by NIMH, will greatly facilitate the improvement of iPSC approaches for high-throughput diagnostic and drug discovery.”
The teams will use iPSCs generated from more than 50 patients with schizophrenia or bipolar disorder so that a wide range of genetic differences is taken into account. By coaxing iPSCs to become four different types of brain cells, the teams will be able to see which types are most affected by specific genetic differences and when those effects may occur during development.
First the researchers must figure out, at the cellular level, what features characterize a given illness in a given brain cell type. To do that, they will assess the cells’ shapes, connections, energy use, division and other properties. They will then develop a way of measuring those characteristics that works on a large scale, such as recording the activity of cells under hundreds of different conditions simultaneously.
Once a reliable, scalable and reproducible test system has been developed, the industry partners will have the opportunity to use it to identify or develop drugs that might combat mental illness.
“This exciting new research has great potential to expedite drug discovery by using human cells from individuals who suffer from these devastating illnesses. Starting with a deeper understanding of each disorder should enable the biopharmaceutical industry to design drug discovery strategies that are focused on molecular pathology,” says Husseini K. Manji, MD, F.R.C.P.C., global therapeutic area head of neuroscience for Janssen Research & Development.
The researchers also expect to develop a large body of data that will shed light on the molecular and genetic differences between bipolar disorder and schizophrenia. And, since other mental health disorders share some of the genetic variations found in schizophrenia and bipolar disorder, the data will likely inform the study of many illnesses.
The National Cooperative Reprogrammed Cell Research Groups program, which is funding the research, was introduced by the National Institute of Mental Health in 2013 to overcome barriers to collaboration by creating precompetitive agreements that harness the unique strengths of academic and industry research. The federal-academic-industry collaboration will bring together leading experts in the fields of stem cells and neuropsychiatric disorders:
Academic Partners:
Hongjun Song, Professor, the Johns Hopkins University School of Medicine
Rusty Gage, Professor, Laboratory of Genetics at the Salk Institute
Sue O’Shea, Director, Michigan Pluripotent Stem Cell Core and Professor, University of Michigan
Anne Bang, Director, Conrad Prebys Center for Chemical Genomics at the Sanford Burnham Prebys Medical Discovery Institute
Industry Partners:
Guang Chen, Janssen fellow, Scientific Director of Neuroscience, Janssen Research & Development
Jeffrey S. Nye, Vice President, Neuroscience Innovation and Partnership Strategy, Janssen Research & Development, J&J Innovation
Husseini K. Manji, Global Therapeutic Area Head of Neuroscience, Janssen Research & Development
Paul Doran, Strategic Alliance Manager, Cellular Dynamics International
Funding Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-13-225.html
Photo caption: Human induced pluripotent stem cells (top left) can be coaxed to become neural progenitor cells (top right) and then neurons (bottom) for modeling human brain development and psychiatric disorders. (Credit: Zhexing Wen and Guo-li Ming, Johns Hopkins Medicine)
